huntingtin gene-silencing divalent siRNAs (Atalanta Therapeutics/Biogen)

N/A

Report date: 2025/03/20 15:56:31
NME

Base Information

Drug Namehuntingtin gene-silencing divalent siRNAs (Atalanta Therapeutics/Biogen)
Drug Alias NameRNAi therapeutics targeting HTT (Atalanta Therapeutics/Biogen)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionHuntingtin inhibitors
TargetsHuntingtin
Therapy Area/IndicationsHuntington Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAtalanta Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAtalanta TherapeuticsBiogen Inc
Inactive CompaniesN/A
Active IndicationsHuntington Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A